Effects of sacubitril/valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy [PDF]
, 2016 Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the ...
Gong, Jianjian +11 more
core +2 more sources
Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
South African Family Practice, 2016 Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care.
M. O.E. Irhuma, M. Vally
doaj +1 more source
Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]
, 2017 Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T. +11 more
core +3 more sources
Frontiers in Public Health, 2022 BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for
Yake Lou +4 more
doaj +1 more source
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF [PDF]
, 2017 Aims: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders.
Chen, Chen-Huan +16 more
core +3 more sources
Renal Failure, 2021 Salt-sensitive (SS) hypertension is accompanied with severe cardiorenal complications. In this condition, elevated blood pressure (BP) resulting from salt retention is associated with counterintuitively lower levels of atrial natriuretic peptide (ANP ...
Iuliia Polina +6 more
doaj +1 more source
What can we learn from SOCRATES: more questions than answers? [PDF]
, 2017 This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core +1 more source
Heterogeneous Pd catalysts as emulsifiers in Pickering emulsions for integrated multistep synthesis in flow chemistry [PDF]
, 2018 Within the “Compartmentalised Smart Factory” approach of the ONE-FLOW project the implementation of different catalysts in “compartments” provided by Pickering emulsions and their application in continuous flow is targeted.
Binks, Bernard P. +6 more
core +1 more source
International Journal of Cardiology: Heart & Vasculature, 2019 Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard +5 more
doaj +1 more source
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]
, 2017 Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Böhm, Michael +12 more
core +1 more source